What we do Mankind Pharma develops, manufactures, and markets broad pharmaceutical formulations and consumer healthcare products across acute and chronic areas in India. |
Founded in 1,991 |
Market share 4th largest pharma in India with a 4.8% market share by value in IPM as of Dec 2025. |
Problem solved Provides affordable, quality pharmaceutical and healthcare products addressing chronic diseases, acute conditions, and consumer wellness needs. |
Top clients or who we serve Serves healthcare providers, retailers, and consumers across India and international markets; primarily B2B and B2C segments. |
Key management Ramesh Juneja (Chairman), Rajeev Juneja (Vice Chairman & MD), Sheetal Arora (CEO & Whole-time Director) |
Our journey and innovations Founded in 1991, expanded from acute pharma to chronic therapies and consumer health, with multiple manufacturing units and key acquisitions like BSV in 2024. |
Where we operate Primarily India with growing exports including US, Nepal, Singapore, UAE, and other global markets. |
Top products or what we offer Pharmaceuticals for cardiovascular, diabetes, neuro, anti-infectives, plus consumer brands like Manforce, Preganews, and specialty oncology/transplant drugs. |
Top brands Manforce (#1 condom brand), Preganews (#1 pregnancy test), Lipirose, Statpure, Dydrogesterone; oncology and super-specialty brands post BSV acquisition. |
Raw materials needed Active pharmaceutical ingredients (APIs), chemicals, vitamins, minerals for formulations. |
Raw materials supplier In-house API manufacturing (Shree Jee acquisition) and external suppliers including domestic and international vendors. |
Recurring vs cyclical contribution Majority revenue is recurring from pharmaceutical formulations sales with some cyclical elements in OTC segment. |
Our industry position Market leader in prescription pharmaceuticals with top rankings in chronic therapy segments and growing super-specialty presence via acquisitions. |
Financial highlights FY 24-25 revenue Rs. 12,207 Cr, net profit Rs. 1,991 Cr; EBITDA margin ~25%, 18.9% YoY revenue growth consolidated. |
Geographical revenue split 87% revenue from India, 13% from exports including US, Nepal, UAE, and others. |
Order book - |
Whats driving growth Growth driven by chronic disease therapies, specialty segment launch, BSV acquisition, expanding consumer healthcare and export markets. |
Our future plans Focus on specialty and super-specialty therapeutic areas, R&D expansion, digital transformation, and brand portfolio scaling. |
Our green promise - |
Our people and values Employee base ~18,000 plus; culture emphasizes innovation, compliance, diversity, and performance-driven growth. |
Key challenges ahead Managing integration of acquisitions, regulatory compliance, competitive market pressures, and sustaining growth momentum. |
Interesting facts First Indian company to commercialize Dydrogesterone; maintained #1 prescription rank in India for 8 years. |
Risks and strategy Risks include market competition and regulatory changes; strategy involves strong R&D, diversified portfolio, and expanding specialty segments. |
